Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Repurchased Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Lisata Therapeutics (LSTA) Receivables - Net (2016 - 2025)

Lisata Therapeutics filings provide 11 years of Receivables - Net readings, the most recent being $502000.0 for Q3 2025.

For the quarter ending Q3 2025, Receivables - Net changed N/A year-over-year to $502000.0, compared with a TTM value of $502000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $900000.0, changed N/A over the prior year.
Receivables - Net hit $502000.0 in Q3 2025 for Lisata Therapeutics, roughly flat from $501000.0 in the prior quarter.
The five-year high for Receivables - Net was $900000.0 in Q4 2024, with the low at $501000.0 in Q2 2025.